Keyphrases
Academic Society
25%
Acute Phase Treatment
25%
Antidepressant Treatment
25%
Antidepressants
100%
Baseline Severity
75%
Best Model
25%
Bupropion
25%
Clinical Practice Guidelines
25%
Confidence Interval
25%
Depression Severity
25%
Double-blind Randomized Trial
25%
Duloxetine
25%
Effect Modification
25%
Effect Modifier
25%
Escitalopram
25%
Individual Participant Data
50%
Individual Participant Data Meta-analysis
100%
Initial Severity
100%
Japan
25%
Major Depressive Disorder
100%
Mirtazapine
25%
Mixed Model Repeated Measures
25%
Paroxetine
25%
Pharmaceutical Companies
25%
Placebo
25%
Placebo-controlled
25%
Positive Coefficients
25%
Psychiatric Disorders
25%
Public-private Partnership
25%
Sensitivity Analysis
25%
Medicine and Dentistry
Antidepressant
100%
Bupropion
25%
Duloxetine
25%
Escitalopram
25%
Major Depressive Episode
100%
Mental Disorder
25%
Meta-Analysis
100%
Mirtazapine
25%
Paroxetine
25%
Placebo
50%
Neuroscience
Antidepressant
100%
Bupropion
25%
Duloxetine
25%
Escitalopram
25%
Major Depressive Disorder
100%
Mental Disorder
25%
Meta-Analysis
100%
Mirtazapine
25%
Paroxetine
25%
Placebo
50%
Pharmacology, Toxicology and Pharmaceutical Science
Antidepressant
100%
Bupropion
25%
Duloxetine
25%
Escitalopram
25%
Major Depression
100%
Mirtazapine
25%
Paroxetine
25%
Placebo
50%
Psychology
Major Depression
100%
Meta-Analysis
100%
Practice Guideline
25%